TY - JOUR
T1 - MFN2 mutation distribution and genotype/phenotype correlation in Charcot-Marie-Tooth type 2
AU - Verhoeven, Kristien
AU - Claeys, Kristl G.
AU - Züchner, Stephan
AU - Schröder, J. Michael
AU - Weis, Joachim
AU - Ceuterick, Chantal
AU - Jordanova, Albena
AU - Nelis, Eva
AU - De Vriendt, Els
AU - Van Hul, Matthias
AU - Seeman, Pavel
AU - Mazanec, Radim
AU - Saifi, Gulam Mustafa
AU - Szigeti, Kinga
AU - Mancias, Pedro
AU - Butler, Ian J.
AU - Kochanski, Andrzej
AU - Ryniewicz, Barbara
AU - De Bleecker, Jan
AU - Van Den Bergh, Peter
AU - Verellen, Christine
AU - Van Coster, Rudy
AU - Goemans, Nathalie
AU - Auer-Grumbach, Michaela
AU - Robberecht, Wim
AU - Milic Rasic, Vedrana
AU - Nevo, Yoram
AU - Tournev, Ivajlo
AU - Guergueltcheva, Velina
AU - Roelens, Filip
AU - Vieregge, Peter
AU - Vinci, Paolo
AU - Moreno, Maria Teresa
AU - Christen, H. J.
AU - Shy, Michael E.
AU - Lupski, James R.
AU - Vance, Jeffery M.
AU - De Jonghe, Peter
AU - Timmerman, Vincent
N1 - Funding Information:
We gratefully acknowledge the participation of all patients and their relatives in this study. We appreciated the contribution of the VIB Genetic Service Facility (http:// www.vibgeneticservicefacility.be/) for genotyping and sequencing. The study was supported by the Fund for Scientific Research (FWO-Flanders), the Medical Foundation Queen Elisabeth (GSKE), the University of Antwerp (UA), the Interuniversity Attraction Poles program of the Belgian Federal Science Policy Office (BELSPO) and the Association Belge contre les Maladies Neuromusculaires (ABMM) to V.T. and P.D.J. Support was provided by National Institute of Health (NIH grants NS 2P01-NS26630-14 and 2R01-NS29416-09) to J.M.V., the Czech Ministry of Health (VZ00064203/6506) to P.S., the Polish State Scientific Committee (KBN) No. 2P05E 112 28 to A.K., and the Austrian Science Fund (FWF, P17494-B14) to M.A.-G. K.V. is a postdoctoral fellow of the FWO-Flanders, Belgium. A.J. received visiting research fellowships from the BELSPO and NATO/FWO, Belgium. P.S. received a European Neurological Society (ENS) fellowship.
PY - 2006/8
Y1 - 2006/8
N2 - Mutations in mitofusin 2 (MFN2) have been reported in Charcot-Marie-Tooth type 2 (CMT2) families. To study the distribution of mutations in MFN2 we screened 323 families and isolated patients with distinct CMT phenotypes. In 29 probands, we identified 22 distinct MFN2 mutations, and 14 of these mutations have not been reported before. All mutations were located in the cytoplasmic domains of the MFN2 protein. Patients presented with a classical but rather severe CMT phenotype, since 28% of them were wheelchair-dependent. Some had additional features as optic atrophy. Most patients had an early onset and severe disease status, whereas a smaller group experienced a later onset and milder disease course. Electrophysiological data showed in the majority of patients normal to slightly reduced nerve conduction velocities with often severely reduced amplitudes of the compound motor and sensory nerve action potentials. Examination of sural nerve specimens showed loss of large myelinated fibres and degenerative mitochondrial changes. In patients with a documented family history of CMT2 the frequency of MFN2 mutations was 33% indicating that MFN2 mutations are a major cause in this population.
AB - Mutations in mitofusin 2 (MFN2) have been reported in Charcot-Marie-Tooth type 2 (CMT2) families. To study the distribution of mutations in MFN2 we screened 323 families and isolated patients with distinct CMT phenotypes. In 29 probands, we identified 22 distinct MFN2 mutations, and 14 of these mutations have not been reported before. All mutations were located in the cytoplasmic domains of the MFN2 protein. Patients presented with a classical but rather severe CMT phenotype, since 28% of them were wheelchair-dependent. Some had additional features as optic atrophy. Most patients had an early onset and severe disease status, whereas a smaller group experienced a later onset and milder disease course. Electrophysiological data showed in the majority of patients normal to slightly reduced nerve conduction velocities with often severely reduced amplitudes of the compound motor and sensory nerve action potentials. Examination of sural nerve specimens showed loss of large myelinated fibres and degenerative mitochondrial changes. In patients with a documented family history of CMT2 the frequency of MFN2 mutations was 33% indicating that MFN2 mutations are a major cause in this population.
KW - Charcot-Marie-Tooth type 2
KW - Genotype-phenotype correlation
KW - Mitofusin 2
UR - http://www.scopus.com/inward/record.url?scp=33747884623&partnerID=8YFLogxK
U2 - 10.1093/brain/awl126
DO - 10.1093/brain/awl126
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 16714318
AN - SCOPUS:33747884623
SN - 0006-8950
VL - 129
SP - 2093
EP - 2102
JO - Brain
JF - Brain
IS - 8
ER -